Effect of Paclitaxel and Cyclophosphamide on Ovarian Cancer and TP53 Status
Author Information
Author(s): B Smith-Sorensen, J Kmrn, R HoWm, A Dorum, C Trop, A-L Borresen-Dale
Primary Institution: The Norwegian Radium Hospital
Hypothesis
Does the TP53 gene status influence the response to paclitaxel therapy in ovarian cancer patients?
Conclusion
Patients treated with paclitaxel and cisplatin had a significantly better relapse-free survival compared to those treated with cyclophosphamide and cisplatin.
Supporting Evidence
- 85% of patients responded positively to paclitaxel/cisplatin therapy compared to 61% for cyclophosphamide/cisplatin.
- 73% of tumor samples had detectable TP53 gene alterations.
- Patients with TP53 mutations had a better outcome with paclitaxel/cisplatin compared to cyclophosphamide/cisplatin.
Takeaway
This study looked at how a gene called TP53 affects the treatment of ovarian cancer with two different drugs. It found that one drug combination worked better than the other.
Methodology
Patients were randomized to receive either paclitaxel and cisplatin or cyclophosphamide and cisplatin, and their TP53 gene status was analyzed.
Limitations
The study had a small sample size and may not fully represent the broader population.
Participant Demographics
Median age at diagnosis was 53 years, with a range of 29-73 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website